COMPANY
ABOUT US
Management team
Board of Directors
Scientific Advisory Board
Business Development
Main Investors
CONTACT US
SCIENCE
SNP-Technology
Intellectual Property
PIPELINE
Overview
OCS-01 Diabetic macular edema
OCS-01 Post Cataract Surgery Inflammation
OCS-02 Uveitis
OCS-02 Dry Eye
NEWS
Press releases
CAREERS
COMPANY
ABOUT US
Management team
Board of Directors
Scientific Advisory Board
Business Development
Main Investors
CONTACT US
SCIENCE
SNP-Technology
Intellectual Property
PIPELINE
Overview
OCS-01 Diabetic macular edema
OCS-01 Post Cataract Surgery Inflammation
OCS-02 Uveitis
OCS-02 Dry Eye
NEWS
Press releases
CAREERS
Press Release 2020
September 1, 2020
OCULIS ESTABLISHES PRESENCE IN U.S. AND APPOINTS SYLVIA CHEUNG AS CHIEF FINANCIAL OFFICER
August 10, 2020
OCULIS REPORTS POSITIVE TOP-LINE DATA FROM SKYGGN (PHASE 2) TRIAL WITH OCS-01 FOR TREATING INFLAMMATION AND PAIN FOLLOWING CATARACT SURGERY
July 27, 2020
OCULIS ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH THE FDA FOR OCS-01 IN TWO OPHTHALMOLOGY INDICATIONS